1. In Vivo
  2. >>Deal-Making

Biopharma Dealmaking Quarterly Statistics, Q1 2014

A look at financing, M&A, and alliance activity January–March 2014

Biopharma financing totaled $9.8 billion, a 53% increase over Q4 2013. Twenty-two M&As were completed with a combined potential value reaching $31.3 billion, and there were 103 biopharma alliances totaling $1.9 billion in potential pre-commercialization value, down 30% from the previous quarter.

During the opening quarter of 2014, biopharma companies raised $9.8 billion (up 53% from Q4), with 18% of the deals having a value of $100 million or greater. (See Exhibit 1.)

Follow-on public offerings accounted for most (40%), with 53 deals bringing in $3.9 billion. In Q1’s largest FOPO, InterMune Inc. netted $233 million. [See Deal] Recent positive Phase...

More from Deal-Making

More from In Vivo